Chats with Chaudhrey Interview with the CEOs from Abzena & Angiex about ADC Development Partnership

Life Science Blogger, Rizwan Chaudhrey sat down with Angiex Inc.’s co-founder & CEO, Paul Jaminet and Abzena’s CEO, Matthew Stober to discuss how their clinical supplies partnership for Angiex’s AGX101 came to be.

AGX101 is a first-in-class TM4SF1-directed Antibody-Drug Conjugate (#ADC) program that just began dosing patients in their Phase I clinical trial.

Abzena supported the development and cGMP manufacturing of AGX101, providing the clinical trial material for Angiex’s Phase 1 trial.

Hear more about their relationship and why Angiex selected Abzena as their CDMO partner for AGX101.

He asked them…
◉  Paul would you be kind enough to give viewers background on Angiex and its programs & mission? 00:58
◉ Matt would you do the same for Abzena and how your mission aligns with Angiex? 02:48
◉ Paul, why did Angiex selected Abzena as their development partner? 04:12
◉ Matt, what support is Abzena providing Angiex & how has the working relationship been? 06:39
◉  Paul, how do you think the relationship has gone so far? 09:14
◉  Paul, what does the future hopefully have in store for AGX101 and your partnership? 10:15
◉  Matt, the same question to you. 11:28
Final question to both of you. ADC have been in the news a lot over the past 18 months, and is one area that there has been investment in the sector.
◉ What do you see the future hold for ADCs? Paul? 13:14
◉ Matt as a company working with a lot of companies looking to develop ADC’s what do you thing the future holds for ADCs? 14:49

If you would like to learn more about the Angiex’s Phase I Study of AGX101, and Abzena’s partnership check out the link to the press release here: Abzena Supplies Clinical Trial Material for Angiex’s Phase I Study of AGX101, a First-in-Class TM4SF1-directed ADC | Abzena